Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 245-251

  Raitakari, Olli T ^a,b   Mäkinen, Ville Petteri ^c   McQueen, Matthew J ^d   Niemi, Jaakko ^c   Juonala, Markus ^a   Jauhiainen, Matti ^e   Salomaa, Veikko ^e   Hannuksela, Minna L ^f   Savolainen, Markku J ^c,f   Kesäniemi, Y Antero ^f   Kovanen, Petri T ^g   Sundvall, Jouko ^e   Solakivi, Tiina ^h   Loo, Britt Marie ^e   Marniemi, Jukka ^e   Hernesniemi, Jussi ^h   Lehtimäki, Terho ^h   Kähönen, Mika ^h   Peltonen, Markku ^e   Leiviskä, Jaana ^e   Jula, Antti ^e   Anand, Sonia S ^d   Miller, Ruby ⁱ   Yusuf, Salim ^d   Viikari, Jorma S A ^a   Ala Korpela, Mika ^c,f   more..

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d MCMASTER UNIVERSITY   (Canada)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g WIHURI RESEARCH INSTITUTE   (Finland)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁱ Six Nations Health Services   (Canada)

Author keywords

Apolipoproteins; Atherosclerosis; Carotid ultrasound; Computational methods; Neural networks

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ARTIFICIAL NEURAL NETWORK; CARDIOVASCULAR RISK; CAROTID ARTERY; CAUCASIAN; CHOLESTEROL BILE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84871397653     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.049     Document Type: Article

References (31)

1. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
2. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996, 94:273-278.
3. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
4. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
5. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
6. McQueen M.J., Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
7. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36:211-228.
8. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
9. Niemi J., Mäkinen V.-P., Tenkanen L., et al. Estimation of VLDL, IDL, LDL, HDL2, apoA-I and apoB from the Friedewald inputs - apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med 2009, 41:451-461.
10. Raitakari O.T., Juonala M., Rönnemaa T., et al. Cohort profile: the cardiovascular risk in young Finns study. Int J Epidemiol 2008, 1220-1226.
11. Health and functional capacity in Finland Baseline results of the health 2000 health examination survey 2004, Publications of the National Public Health Institute, Helsinki, B12/2004.
12. Leiviska J., Sundvall J., Alfthan G., Jauhiainen M., Salomaa V., Apolipoprotein A.-I. apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study. Clin Chim Acta 2011, 412:1146-1150.
13. Kotronen A., Yki-Järvinen H., Männisto S., et al. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health 2010, 10:237.
14. Anand S.S., Yusuf S., Vuksan V., et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000, 356:279-284.
15. Raitakari O.T., Juonala M., Kähönen M., et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood - the cardiovascular risk in young Finns study. JAMA 2003, 290:2277-2283.
16. Samani N.J., Raitakari O.T., Sipila K., et al. Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1679-1683.
17. Jänis M.T., Siggins S., Tahvanainen E., et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res 2004, 45:2303-2309.
18. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
19. Anderson K.M., Odell P.M., Wilson P.W., Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 1991, 121:293-298.
20. Sierra-Johnson J., Fisher R.M., Romero-Corral A., et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2008, 30:710-717.
21. Juonala M., Viikari J.S., Kähönen M., et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol 2008, 52:293-299.
22. Rodvold D.M., McLeod D.G., Brandt J.M., Snow P.B., Murphy G.P. Introduction to artificial neural networks for physicians: taking the lid off the black box. Prostate 2001, 46:39-44.
23. Baxt W.G. Application of artificial neural networks to clinical medicine. Lancet 1995, 346:1135-1138.
24. Hart A., Wyatt J. Evaluating black-boxes as medical decision aids: issues arising from a study of neural networks. Med Inform (Lond) 1990, 15:229-236.
25. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
26. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
27. Denke M.A. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005, 112:3368-3370.
28. Den Ruijter H.M., Peters S.A., Anderson T.J., et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012, 308:796-803.
29. Silva R.A., Huang R., Morris J., et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci U S A 2008, 105:12176-12181.
30. de Graaf J., Couture P., Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Pract 2008, 4:608-618.
31. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.